Assessment of physical function Physical function is a central aspect of life for patients with RA and thus a major focus of patient care. In clinical practice, function is most commonly evaluated with questionnaires, typically the Health Assessment Questionnaire (HAQ). ACR-preferred measures for assessment of physical function for routine clinical use HAQ-II • a simplifed HAQ:10 questions with 4 levels of diffculty each. Multidimensional HAQ (MD-HAQ) • The forms for the HAQ, the HAQ-II, and the MD-HAQ can be obtained from online sources, such as rheuminfo.com/physician-tools/health-assessment-questionnaires-haq-haq-ii-mdhaq/ Physical Function 10-item Short Form (Patient-Reported Outcomes Measurement Information System Physical Function 10-item Short Form [PROMIS PF10a]) • a short patient questionnaire of 10 questions related to physical function that are categorized into 5 states of diffculty. https://www.healthmeasures.net/explore-measurement-systems/promis Assessment of fatigue Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-F) • a brief (13 items) measure for assessment of self-reported fatigue and its impact upon daily activities and function.Scores range from 0 to 52, with higher scores refecting less fatigue. • FACIT-F has been validated for use in patients with RA; can be applied also in patients with other rheumatic diseases. 1 • FACIT website: http://www.facit.org/ Ref: 1. Cella D. J Rheumatol. 2005;32:811-9. Singh H. J Clin Rheumatol. 2014;20(2):87-90. Elera-Fitzcarrald C. Arthritis Care and Research, 2020;72, S10:369–409. Response Criteria Response criteria are mainly used for clinical trials and less frequently in daily practice. ACR response criteria ACR response criteria were developed to best discriminate the effects of active drug from placebo in clinical trials.* ACR response is scored as a percentage of improvement, comparing disease activity at two discrete time points (usually baseline and post-baseline comparison). The ACR response criteria is a dichotomous variable with a positive (=responder) or negative (=non-responder) outcome. The ACR20 response has been the preferred endpoint for clinical trials because it discriminates optimally between active treatment and placebo.** * Felson DT. Arthritis Rheum. 1995;38:727–35. ** Felson DT, Arthritis Rheum. 1998;41:1564–70 8
RkJQdWJsaXNoZXIy MjgzNzA=